Stay updated with breaking news from Anna Kamilli. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- COVID-19 vaccine efforts to be re-allocated to accelerate the development of second-generation program in collaboration with GSK- First-generation vaccine candidate, CVnCoV, to be withdrawn from regulatory
Press release content from Accesswire. The AP news staff was not involved in its creation.
CureVac Appoints Klaus Edvardsen as Chief Development Officer TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 2, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Klaus Edvardsen, MD, PhD, as Chief Development Officer. The appointment of Dr. Edvardsen will take effect on August 1, 2021. "We are very happy to welcome Dr. Edvardsen to the CureVac leadership team," said Jean Stéphenne, Chairman of the Supervisory Board of C...
Investegate announcements from CureVac, CureVac Appoints Klaus Edvardsen as Chief Development Officer
CureVac CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation DGAP-News: CureVac / Key word(s): Study CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation 28.05.2021 / 22:30 CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation - COVID-19 cases TÜBINGEN, Ge...